rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2026-3321CWYNAZrpcardio-3321Research ArticleREVIEWSОБЗОРЫThe role of the metabotropic glutamate receptor 1 signaling pathway in the development of cardiovascular pathologyРоль сигнального пути метаботропного глутаматного рецептора 1 в развитии сердечно-сосудистой патологииhttps://orcid.org/0000-0002-9315-3801ЛевшинаА. Р.LevshinaA. R.

Левшина Анна Романовна 

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Anna R. Levshina 

Petroverigsky Lane, 10, bld. 3, Moscow, 101990 

levshina.ar@gmail.comhttps://orcid.org/0000-0002-6108-3538ГумановаН. Г.GumanovaN. G.

Гуманова Надежда Георгиевна 

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Nadegda G. Gumanova 

Petroverigsky Lane, 10, bld. 3, Moscow, 101990 

levshina.ar@gmail.comhttps://orcid.org/0009-0006-9923-1109ВосканянЛ. В.VoskanianL. V.

Восканян Лидия Ваагновна 

ул. Трубецкая, д. 8, стр. 2, Москва,119048 

Lidia V. Voskanian 

8-2 Trubetskaya str., Moscow, 119048 

https://orcid.org/0000-0003-3119-6758ШаноянА. С.ShanoyanA. S.

Шаноян Артем Сергеевич  

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Artem S. Shanoyan 

Petroverigsky Lane, 10, bld. 3, Moscow, 101990 

levshina.ar@gmail.comhttps://orcid.org/0000-0002-3905-735XВасильевД. К.VasilievD. K.

Васильев Дмитрий Константинович 

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Dmitry K. Vasiliev 

Petroverigsky Lane, 10, bld. 3, Moscow, 101990 

levshina.ar@gmail.comhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна  

Петроверигский пер., д. 10, стр. 3, Москва, 101990

Oksana M. Drapkina 

Petroverigsky Lane, 10, bld. 3, Moscow, 101990 

ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииРоссияNational Medical Research Center for therapy and Preventive MedicineRussian FederationФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)РоссияSechenov First Moscow State Medicine UniversityRussian Federation202617062026222160166Copyright © Levshina A.R., Gumanova N.G., Voskanian L.V., Shanoyan A.S., Vasiliev D.K., Drapkina O.M., 20262026Левшина А.Р., Гуманова Н.Г., Восканян Л.В., Шаноян А.С., Васильев Д.К., Драпкина О.М.Levshina A.R., Gumanova N.G., Voskanian L.V., Shanoyan A.S., Vasiliev D.K., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/3321

Metabotropic glutamate receptor 1 (mGluR1), traditionally studied in the context of neuronal signaling, has recently gained attention as a potential contributor to the pathogenesis of cardiovascular diseases. This review summarises current evidence on the role of mGluR1 in neurodegenerative, oncological, and — most importantly — cardiovascular diseases. We discuss the receptor structure, its classification as a GPCR family member, and the features of its intracellular signaling, including activation of the MAPK/ERK and PI3K/Akt pathways and regulation of transcription factors. It has been shown that, in addition to the central nervous system, mGluR1 is expressed in immune cells, the endothelium, vascular smooth muscle cells, and cardiomyocytes, suggesting its involvement in regulating inflammation, proliferation, and angiogenesis — key processes in atherogenesis. Special attention is given to data on glutamate accumulation in unstable atherosclerotic plaques and its association with local inflammation. We also note the lack of clinical studies evaluating mGluR1 concentrations in patients with coronary artery disease. Further investigation of mGluR1 as a potential biomarker and molecular target in cardiovascular pathology represents a promising direction.

Метаботропный глутаматный рецептор 1 — mGluR1 (metabotropic glutamate receptor 1), традиционно рассматриваемый в контексте нейрональной сигнализации, в последние годы привлекает внимание как потенциальный участник патогенеза сердечно-сосудистой заболеваний. В обзоре обобщены современные данные о роли mGluR1 в нейродегенеративных, онкологических и, прежде всего, сердечно-сосудистых заболеваниях. Рассмотрена структура рецептора, его принадлежность к семейству GPCR, а также особенности внутриклеточной сигнализации, включая активацию MAPK/ERK-, PI3K/Akt-зависимых путей и регуляцию факторов транскрипции. Показано, что, помимо центральной нервной системы, mGluR1 экспрессируется в иммунных клетках, эндотелии, гладкомышечных клетках сосудов и кардиомиоцитах, что указывает на его роль в регуляции воспаления, пролиферации и ангиогенеза — ключевых процессов для атерогенеза. Особое внимание уделено данным о накоплении глутамата в нестабильных атеросклеротических бляшках и его связи с локальным воспалением. Отмечается дефицит клинических исследований, оценивающих концентрацию mGluR1 у пациентов с ишемической болезнью сердца. Перспективной задачей является дальнейшее изучение mGluR1 как потенциального биомаркера и молекулярной мишени при сердечно-сосудистой патологии.

mGluR1метаботропные глутаматные рецепторыатеросклерозсердечно-сосудистые заболеванияGPCRвоспалениеmGluR1metabotropic glutamate receptorsatherosclerosiscardiovascular diseasesGPCRinflammationРабота выполнена в рамках госзадания № 124013100889-7.ReferencesHerrington W, Lacey B, Sherliker P, et al. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ Res. 2016;118(4):535-46. DOI: 10.1161/circresaha.115.307611.Herrington W, Lacey B, Sherliker P, et al. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ Res. 2016;118(4):535-46. DOI: 10.1161/circresaha.115.307611.Libby P, Hansson GK. From Focal Lipid Storage to Systemic Inflammation. J Am Coll Cardiol. 2019;74(12):1594-607. DOI: 10.1016/j.jacc.2019.07.061.Libby P, Hansson GK. From Focal Lipid Storage to Systemic Inflammation. J Am Coll Cardiol. 2019;74(12):1594-607. DOI: 10.1016/j.jacc.2019.07.061.Васильев Д.К., Левшина А.Р., Гуманова Н.Г., Драпкина О.М. Белки межклеточной адгезии P-, E- и H-кадгерины как биомаркеры онкологических и сердечнососудистых заболеваний. Профилактическая медицина. 2025;28(7):100-5. DOI: 10.17116/profmed202528071100.Vasilyev DK, Levshina AR, Gumanova NG, Drapkina OM. Intercellular adhesion proteins: P-, E-, H-cadherins as oncological and cardiovascular diseases’ biomarkers. Russian Journal of Preventive Medicine. 2025;28(7):100-5. (In Russ.) DOI: 10.17116/profmed202528071100.Гуманова Н.Г. Аналитический комплекс биохимических маркеров для доклинической диагностики и профилактики сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика. 2019;18(5):117-27. DOI: 10.15829/1728-8800-2019-5-117-127.Gumanova NG. Analytical complex of biochemical markers for preclinical diagnosis and prevention of cardiovascular diseases. Cardiovascular Therapy and Prevention. 2019;18(5):117-27. (In Russ.) DOI: 10.15829/1728-8800-2019-5-117-127.Tsimikas S. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):157-64. DOI: 10.1097/MED.0000000000000237.Tsimikas S. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):157-64. DOI: 10.1097/MED.0000000000000237.Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk. JAMA Cardio. 2022;7(3):257-8. DOI: 10.1001/JAMACARDIO.2021.5080.Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk. JAMA Cardio. 2022;7(3):257-8. DOI: 10.1001/JAMACARDIO.2021.5080.Гуманова Н.Г., Климушина М.В., Богданова Н.Л. и др. Валидные кардиоспецифические биохимические маркеры. Часть II. Кардиоваскулярная терапия и профилактика. 2020;19(5):2588. DOI: 10.15829/1728-8800-2020-2588.Gumanova NG, Klimushina MV, Bogdanova NL, et al. Valid cardiac biochemical markers. Part II. Cardiovascular Therapy and Prevention. 2020;19(5):2588. (In Russ.) DOI: 10.15829/1728-8800-2020-2588.Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-26. DOI: 10.1089/jir.2008.0027.Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313-26. DOI: 10.1089/jir.2008.0027.Georgakis MK, de Lemos JA, Ayers C, et al. Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies. JAMA Cardiol. 2021;6(5):587-92. DOI: 10.1001/jamacardio.2020.5392.Georgakis MK, de Lemos JA, Ayers C, et al. Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies. JAMA Cardiol. 2021;6(5):587-92. DOI: 10.1001/jamacardio.2020.5392.Mehta NN, deGoma E, Shapiro MD. IL-6 and Cardiovascular Risk: A Narrative Review. Curr Atheroscler Rep. 2024;27(1):12. DOI: 10.1007/s11883-024-01259-7.Mehta NN, deGoma E, Shapiro MD. IL-6 and Cardiovascular Risk: A Narrative Review. Curr Atheroscler Rep. 2024;27(1):12. DOI: 10.1007/s11883-024-01259-7.Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56(2):177-185. DOI: 10.1373/clinchem.2009.126706.Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56(2):177-185. DOI: 10.1373/clinchem.2009.126706.Gumanova NG, Vasilyev DK, Bogdanova NL, et al. P-, E-, and H-cadherins differ in their relationships with coronary stenosis, cardiovascular outcomes, and unplanned recurrent revascularization. J Mol Cell Cardiol Plus. 2024;9:100091. DOI: 10.1016/j.jmccpl.2024.100091.Gumanova NG, Vasilyev DK, Bogdanova NL, et al. P-, E-, and H-cadherins differ in their relationships with coronary stenosis, cardiovascular outcomes, and unplanned recurrent revascularization. J Mol Cell Cardiol Plus. 2024;9:100091. DOI: 10.1016/j.jmccpl.2024.100091.Ajoolabady A, Pratico D, Lin L, et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis. 2024;15(11):817. DOI: 10.1038/s41419-024-07166-8.Ajoolabady A, Pratico D, Lin L, et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis. 2024;15(11):817. DOI: 10.1038/s41419-024-07166-8.Bekbossynova M, Saliev T, Ivanova-Razumova T, et al. Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis. J Clin Med. 2025;14(7):2352. DOI: 10.3390/jcm14072352.Bekbossynova M, Saliev T, Ivanova-Razumova T, et al. Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis. J Clin Med. 2025;14(7):2352. DOI: 10.3390/jcm14072352.Li L, Lai L, Qiu D, et al. P2Y6 receptor: A promising therapeutic target for atherosclerosis. Eur J Pharmacol. 2025;998:177513. DOI: 10.1016/j.ejphar.2025.177513.Li L, Lai L, Qiu D, et al. P2Y6 receptor: A promising therapeutic target for atherosclerosis. Eur J Pharmacol. 2025;998:177513. DOI: 10.1016/j.ejphar.2025.177513.Gumanova NG, Vasilyev DK, Bogdanova NL, et al. Application of an antibody microarray for serum protein profiling of coronary artery stenosis. Biochem Biophys Res Commun. 2022;631:55-63. DOI: 10.1016/j.bbrc.2022.09.053.Gumanova NG, Vasilyev DK, Bogdanova NL, et al. Application of an antibody microarray for serum protein profiling of coronary artery stenosis. Biochem Biophys Res Commun. 2022;631:55-63. DOI: 10.1016/j.bbrc.2022.09.053.Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995;34(1):1-26. DOI: 10.1016/0028-3908(94)00129-G.Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995;34(1):1-26. DOI: 10.1016/0028-3908(94)00129-G.Gerber U, Gee C, Benquet P. Metabotropic glutamate receptors: intracellular signaling pathways. Curr Opin Pharmacol. 2007;7(1):56-61. DOI: 10.1016/j.coph.2006.08.008.Gerber U, Gee C, Benquet P. Metabotropic glutamate receptors: intracellular signaling pathways. Curr Opin Pharmacol. 2007;7(1):56-61. DOI: 10.1016/j.coph.2006.08.008.Kwon Y, Mehta S, Zhang J. Probing spatiotemporally organized GPCR signaling using genetically encoded molecular tools. Exp Mol Med. 2025;57(7):1432-42. DOI: 10.1038/s12276-025-01485-2.Kwon Y, Mehta S, Zhang J. Probing spatiotemporally organized GPCR signaling using genetically encoded molecular tools. Exp Mol Med. 2025;57(7):1432-42. DOI: 10.1038/s12276-025-01485-2.Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010;50:295-322. DOI: 10.1146/annurev.pharmtox.011008.145533..Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010;50:295-322. DOI: 10.1146/annurev.pharmtox.011008.145533..Yadav R, Zaccolo M. GPCR signaling via cAMP nanodomains. Biochem J. 2025;482(10):519-33. DOI: 10.1042/BCJ20253088.Yadav R, Zaccolo M. GPCR signaling via cAMP nanodomains. Biochem J. 2025;482(10):519-33. DOI: 10.1042/BCJ20253088.Luttrell LM. Minireview: More than just a hammer: ligand “bias” and pharmaceutical discovery. Mol Endocrinol. 2014;28(3):281-94. DOI: 10.1210/me.2013-1314.Luttrell LM. Minireview: More than just a hammer: ligand “bias” and pharmaceutical discovery. Mol Endocrinol. 2014;28(3):281-94. DOI: 10.1210/me.2013-1314.Wang J, Gareri C, Rockman HA. G-Protein–Coupled Receptors in Heart Disease. Circ Res. 2018;123(6):716-35. DOI: 10.1161/CIRCRESAHA.118.311403. Erratum in: Circ Res. 2018;123(10):e34. DOI: 10.1161/RES.0000000000000235.Wang J, Gareri C, Rockman HA. G-Protein–Coupled Receptors in Heart Disease. Circ Res. 2018;123(6):716-35. DOI: 10.1161/CIRCRESAHA.118.311403. Erratum in: Circ Res. 2018;123(10):e34. DOI: 10.1161/RES.0000000000000235.Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 2013;53:531-56. DOI: 10.1146/annurev-pharmtox-032112-135923.Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 2013;53:531-56. DOI: 10.1146/annurev-pharmtox-032112-135923.Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3(9):639-50. DOI: 10.1038/nrm908.Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3(9):639-50. DOI: 10.1038/nrm908.Balbi M, Bonanno G, Bonifacino T, Milanese M. The Physio-Pathological Role of Group I Metabotropic Glutamate Receptors Expressed by Microglia in Health and Disease with a Focus on Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2023;24(6):5240. DOI: 10.3390/ijms24065240.Balbi M, Bonanno G, Bonifacino T, Milanese M. The Physio-Pathological Role of Group I Metabotropic Glutamate Receptors Expressed by Microglia in Health and Disease with a Focus on Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2023;24(6):5240. DOI: 10.3390/ijms24065240.Su LD, Wang N, Han J, Shen Y. Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective. Neuroscientist. 2022;28(5):453-68. DOI: 10.1177/10738584211021018.Su LD, Wang N, Han J, Shen Y. Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective. Neuroscientist. 2022;28(5):453-68. DOI: 10.1177/10738584211021018.Wang H, Zhuo M. Group I metabotropic glutamate receptor-mediated gene transcription and implications for synaptic plasticity and diseases. Front Pharmacol. 2012;3:189. DOI: 10.3389/fphar.2012.00189.Wang H, Zhuo M. Group I metabotropic glutamate receptor-mediated gene transcription and implications for synaptic plasticity and diseases. Front Pharmacol. 2012;3:189. DOI: 10.3389/fphar.2012.00189.Ferraguti F, Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res. 2006;326(2):483-504. DOI: 10.1007/s00441-006-0266-5.Ferraguti F, Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res. 2006;326(2):483-504. DOI: 10.1007/s00441-006-0266-5.Alborghetti M, Ceccherelli A, Caridi M, et al. Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson’s disease. NPJ Parkinsons Dis. 2025;11(1):290. DOI: 10.1038/s41531-025-01138-1.Alborghetti M, Ceccherelli A, Caridi M, et al. Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson’s disease. NPJ Parkinsons Dis. 2025;11(1):290. DOI: 10.1038/s41531-025-01138-1.Senter RK, Ghoshal A, Walker AG, et al. The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Curr Neuropharmacol. 2016;14(5):455-73. DOI: 10.2174/1570159x13666150421003225.Senter RK, Ghoshal A, Walker AG, et al. The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Curr Neuropharmacol. 2016;14(5):455-73. DOI: 10.2174/1570159x13666150421003225.Солнцева Е.И., Рогозин П.Д., Скребицкий В.Г. Метаботропные глутаматные рецепторы первой группы (mGluR1/5) и нейродегенеративные заболевания. Анналы клинической и экспериментальной неврологии. 2019;13(4):54-64. DOI: 10.25692/ACEN.2019.4.8.Solntseva EI, Rogozin PD, Skrebitsky VG. Group I metabotropic glutamate receptors (mGluR1/5) and neurodegenerative diseases. Annals of Сlinical and Experimental Neurology 2019;13(4):54-64. (In Russ) DOI: 10.25692/ACEN.2019.4.8.Biber K, Laurie DJ, Berthele A, et al. Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J Neurochem. 1999;72(4):1671-80. DOI: 10.1046/j.1471-4159.1999.721671.x.Biber K, Laurie DJ, Berthele A, et al. Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J Neurochem. 1999;72(4):1671-80. DOI: 10.1046/j.1471-4159.1999.721671.x.Hermans E, Challiss RA. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-proteincoupled receptors. Biochem J. 2001;359(Pt 3):465-84. DOI: 10.1042/0264-6021:3590465.Hermans E, Challiss RA. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-proteincoupled receptors. Biochem J. 2001;359(Pt 3):465-84. DOI: 10.1042/0264-6021:3590465.Pacheco R, Ciruela F, Casadó V, et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J Biol Chem. 2004;279(32):33352-8. DOI: 10.1074/jbc.M401761200.Pacheco R, Ciruela F, Casadó V, et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J Biol Chem. 2004;279(32):33352-8. DOI: 10.1074/jbc.M401761200.Bastiaansen AEM, Timmermans AM, Smid M, et al. Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer. Sci Rep. 2020;10(1):22292. DOI: 10.1038/s41598-020-79248-4.Bastiaansen AEM, Timmermans AM, Smid M, et al. Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer. Sci Rep. 2020;10(1):22292. DOI: 10.1038/s41598-020-79248-4.Dolfi SC, Medina DJ, Kareddula A, et al. Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget. 2017;8(27):44639-53. DOI: 10.18632/oncotarget.17961.Dolfi SC, Medina DJ, Kareddula A, et al. Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget. 2017;8(27):44639-53. DOI: 10.18632/oncotarget.17961.Yi H, Talmon G, Wang J. Glutamate in cancers: from metabolism to signaling. J Biomed Res. 2020.;34(4):260-70. DOI: 10.7555/JBR.34.20190037.Yi H, Talmon G, Wang J. Glutamate in cancers: from metabolism to signaling. J Biomed Res. 2020.;34(4):260-70. DOI: 10.7555/JBR.34.20190037.Yu LJ, Wall BA, Wangari-Talbot J, Chen S. Metabotropic glutamate receptors in cancer. Neuropharmacology. 2017;115:193–202. DOI: 10.1016/j.neuropharm.2016.02.011.Yu LJ, Wall BA, Wangari-Talbot J, Chen S. Metabotropic glutamate receptors in cancer. Neuropharmacology. 2017;115:193–202. DOI: 10.1016/j.neuropharm.2016.02.011.Martino JJ, Wall BA, Mastrantoni E, et al. Chen S. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene. 2013;32(37):4366–76. DOI: 10.1038/onc.2012.471.Martino JJ, Wall BA, Mastrantoni E, et al. Chen S. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene. 2013;32(37):4366–76. DOI: 10.1038/onc.2012.471.Eddy K, Eddin MN, Fateeva A, et al. Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression. Cells. 2022;11(18):2857. DOI: 10.3390/cells11182857Eddy K, Eddin MN, Fateeva A, et al. Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression. Cells. 2022;11(18):2857. DOI: 10.3390/cells11182857Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med. 2019;18(3):121-6. DOI: 10.4103/aam.aam_56_18.Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med. 2019;18(3):121-6. DOI: 10.4103/aam.aam_56_18.Dunaway LS, Mills WA 3rd, Eyo UB, Isakson BE. The Cells of the Vasculature: Advances in the Regulation of Vascular Tone in the Brain and Periphery. Basic Clin Pharmacol Toxicol. 2025;136(5):e70023. DOI: 10.1111/bcpt.70023.Dunaway LS, Mills WA 3rd, Eyo UB, Isakson BE. The Cells of the Vasculature: Advances in the Regulation of Vascular Tone in the Brain and Periphery. Basic Clin Pharmacol Toxicol. 2025;136(5):e70023. DOI: 10.1111/bcpt.70023.Medzhitov R. The spectrum of inflammatory responses. Science. 2021;374(6571):1070-5. DOI: 10.1126/science.abi5200.Medzhitov R. The spectrum of inflammatory responses. Science. 2021;374(6571):1070-5. DOI: 10.1126/science.abi5200.Bäck M, Yurdagul A Jr, Tabas I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389-406. DOI: 10.1038/s41569-019-0169-2.Bäck M, Yurdagul A Jr, Tabas I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389-406. DOI: 10.1038/s41569-019-0169-2.Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855): 524-33. DOI: 10.1038/s41586-021-03392-8.Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855): 524-33. DOI: 10.1038/s41586-021-03392-8.Heneka MT, van der Flier WM, Jessen F, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025;25(5):321-52. DOI: 10.1038/s41577-024-01104-7.Heneka MT, van der Flier WM, Jessen F, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025;25(5):321-52. DOI: 10.1038/s41577-024-01104-7.Durante W. Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19. Int J Mol Sci. 2023;24(8):7593. DOI: 10.3390/ijms24087593.Durante W. Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19. Int J Mol Sci. 2023;24(8):7593. DOI: 10.3390/ijms24087593.Sun H, Koike T, Ichikawa T, et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005;167(4):1139-48. DOI: 10.1016/S0002-9440(10)61202-3.Sun H, Koike T, Ichikawa T, et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005;167(4):1139-48. DOI: 10.1016/S0002-9440(10)61202-3.Gumanova NG, Deev AD, Kots AY, Shalnova SA. Elevated levels of serum nitrite and nitrate, NOx, are associated with increased total and cardiovascular mortality in an 8-year follow-up study. Eur J Clin Invest. 2019;49(3):e13061. DOI: 10.1111/eci.13061.Gumanova NG, Deev AD, Kots AY, Shalnova SA. Elevated levels of serum nitrite and nitrate, NOx, are associated with increased total and cardiovascular mortality in an 8-year follow-up study. Eur J Clin Invest. 2019;49(3):e13061. DOI: 10.1111/eci.13061.Jin H, Zhang C, Nagenborg J, Juhasz P, et al. Genome-scale metabolic network of human carotid plaque reveals the pivotal role of glutamine/glutamate metabolism in macrophage modulating plaque inflammation and vulnerability. Cardiovasc Diabetol. 2024;23(1):240. DOI: 10.1186/s12933-024-02339-3.Jin H, Zhang C, Nagenborg J, Juhasz P, et al. Genome-scale metabolic network of human carotid plaque reveals the pivotal role of glutamine/glutamate metabolism in macrophage modulating plaque inflammation and vulnerability. Cardiovasc Diabetol. 2024;23(1):240. DOI: 10.1186/s12933-024-02339-3.Kalev-Zylinska ML, Green TN, Morel-Kopp MC, et al. N-methyl-D-aspartate receptors amplify activation and aggregation of human platelets. Thromb Res. 2014;133(5):837-47. DOI: 10.1016/j.thromres.2014.02.011.Kalev-Zylinska ML, Green TN, Morel-Kopp MC, et al. N-methyl-D-aspartate receptors amplify activation and aggregation of human platelets. Thromb Res. 2014;133(5):837-47. DOI: 10.1016/j.thromres.2014.02.011.Morrell CN. Glutamate mediates platelet activation through the AMPA receptor. J Exp Med. 2008;205(3):575-84. DOI: 10.1084/jem.20071474.Morrell CN. Glutamate mediates platelet activation through the AMPA receptor. J Exp Med. 2008;205(3):575-84. DOI: 10.1084/jem.20071474.Vincent A, Sportouch C, Covinhes A, et al. Cardiac mGluR1 metabotropic receptors in cardioprotection. Cardiovasc Res. 2017;113(6):644-55. DOI: 10.1093/cvr/cvx024.Vincent A, Sportouch C, Covinhes A, et al. Cardiac mGluR1 metabotropic receptors in cardioprotection. Cardiovasc Res. 2017;113(6):644-55. DOI: 10.1093/cvr/cvx024.Li RT, Li Y, Wang BW, et al. Relationship between plasma glutamate and cardiovascular disease risk in Chinese patients with type 2 diabetes mellitus by gender. Front Endocrinol (Lausanne). 2023;14:1095550. DOI: 10.3389/fendo.2023.1095550.Li RT, Li Y, Wang BW, et al. Relationship between plasma glutamate and cardiovascular disease risk in Chinese patients with type 2 diabetes mellitus by gender. Front Endocrinol (Lausanne). 2023;14:1095550. DOI: 10.3389/fendo.2023.1095550.

The authors declare that there are no conflicts of interest present.